NeoGenomics NEO Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$17.11M+34.0% | -$9.88M+35.5% | -$27.13M-53.3% | -$45.09M-142% | -$25.92M+4.2% | ||
| $8.78M-6.3% | $8.76M-10.8% | $8.8M-8.5% | $9.14M-6.2% | $9.37M-5.4% | ||
| $9.64M-10.4% | $8.04M-3.4% | $10.31M— | $12.21M+38.2% | $10.75M+38.3% | ||
| $769K+42.1% | $2.69M+73.1% | —— | $993K+109% | $541K-31.9% | ||
| $8.18M+1,125% | $4.21M— | $2.37M-51.2% | -$1.07M-117% | $668K-92.6% | ||
| $1.27M-58.0% | $28K-98.8% | —— | $4.12M+37.4% | $3.02M+179% | ||
| $718K-37.2% | -$6.59M-62.5% | -$5.82M-216% | $6.58M+236% | $1.14M+928% | ||
| -$7M+69.5% | -$4.1M-140% | —— | —— | -$22.96M-23.7% | ||
| $1.4M-55.1% | -$3.21M-157% | $514K-66.2% | -$1.97M+14.1% | $3.11M+57.1% | ||
| $402K-47.9% | -$326K— | $343K+662% | -$1.11M-615% | $772K+1,454% | ||
| $7.63M-8.7% | $7.63M-8.7% | $7.63M-8.7% | $8.12M-2.8% | $8.36M0.0% | ||
| -$1.3M-19.2% | -$1.23M+28.0% | -$795K+18.8% | —— | -$1.09M+23.9% | ||
| -$8.14M+67.9% | $1.34M-86.3% | $8.88M— | $20.33M— | -$25.33M+2.3% | ||
| $5M+11.1% | $7.87M-32.1% | $8.31M-23.0% | $6.32M-51.7% | $4.5M-19.4% | ||
| $0-100% | $0-100% | $9M+23.6% | $3M-85.3% | $8.06M-59.9% | ||
| -$5M-240% | -$6.31M— | -$277K— | -$9.31M-227% | $3.56M-75.5% | ||
| -$338K-136% | $431K-37.3% | $765K-35.0% | -$1.18M-160% | $949K+16.3% | ||
| -$338K-136% | —— | —— | -$202.43M-10,397% | $949K+16.3% | ||
| -$13.48M+35.3% | -$4.5M-190% | $0-100% | -$191.47M-926% | -$20.82M-96.9% | ||
| $431K+43,000% | $1K-99.9% | $432K-3.6% | $1.26M-0.2% | $1K-99.8% | ||
| $0— | $57K— | $0-100% | $458K+426% | $0-100% | ||
| $7.63M-8.7% | $7.63M-8.7% | $7.63M-8.7% | $8.12M-2.8% | $8.36M0.0% | ||
| $8.78M-6.3% | $8.76M-10.8% | $8.8M-8.5% | $9.14M-6.2% | $9.37M-5.4% | ||
| $718K-37.2% | -$6.59M-62.5% | -$5.82M-216% | $6.58M+236% | $1.14M+928% | ||
| $769K+42.1% | $2.69M+73.1% | —— | $993K+109% | $541K-31.9% | ||
| -$1.3M-19.2% | -$1.23M+28.0% | -$795K+18.8% | —— | -$1.09M+23.9% | ||
| $1.4M-55.1% | -$3.21M-157% | $514K-66.2% | -$1.97M+14.1% | $3.11M+57.1% | ||
| —— | $125K— | $125K— | $125K— | $125K— | ||
| $0-100% | $0-100% | $9M+23.6% | $3M-85.3% | $8.06M-59.9% | ||
| $4.32M+214% | $300K— | $499K— | —— | $1.38M+65.6% | ||
| —— | $7.5K+115% | $7.5K+115% | $7.5K+115% | $7.5K+115% | ||
| -$1.3M-19.2% | -$1.23M+28.0% | -$795K+18.8% | —— | -$1.09M+23.9% | ||
| $1.72M+8.6% | $1.71M-10.0% | $1.69M-24.4% | $1.77M-26.0% | $1.58M-34.0% | ||
| —— | $516.5K— | $516.5K— | $516.5K— | $516.5K— | ||
| —— | $1.6M+937% | $1.6M+937% | $1.6M+937% | $1.6M+937% | ||
| $0— | $57K— | $0-100% | $458K+426% | $0-100% | ||
| -$13.14M+56.0% | -$6.53M-263% | —— | —— | -$29.83M+5.3% | ||
| -$13.14M+56.0% | -$6.53M-263% | —— | —— | -$29.83M+5.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does NeoGenomics generate?
- NeoGenomics (NEO) generated $22.4M in operating cash flow over the trailing twelve months.
- What is NeoGenomics's free cash flow?
- After $27.5M of capital expenditures, NeoGenomics's free cash flow was -$51.3M over the trailing twelve months, down 19.8% year over year.
- Where does NeoGenomics's cash flow data come from?
- Every line is extracted from NeoGenomics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
